Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-week, randomised, double-blind, placebo-controlled, parallel three-group study to assess the safety, tolerability and efficacy of two dose levels of PBT2 to slow progression of disease in patients with early Alzheimer's disease

Next Previous
X
Search
Trial Profile

A 12-week, randomised, double-blind, placebo-controlled, parallel three-group study to assess the safety, tolerability and efficacy of two dose levels of PBT2 to slow progression of disease in patients with early Alzheimer's disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PBT 2 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EURO
  • Sponsors Alterity Therapeutics

    • Most Recent Events

    • 17 Jul 2014 According to the Prana Biotechnology media release, data from this trial was presented at the Alzheimer's Association International Conference 12-14 Jul 2014.
    • 10 Jul 2009 Results, as part of a featured research symposium, will be presented at the 2009 International Conference on Alzheimer's Disease (ICAD) according to a Prana Biotechnology media release.
    • 07 Aug 2008 Results published in the Lancet Neurology Journal.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top